// App-Quantinova.ai

2877 : Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis

Researchers

Presenter

  • Melinda Gooderham

Principal Investigators

  • Akimichi Morita

  • Alan Kivitz

  • Ranjeeta Sinvhal

  • Andrew Topp

  • Graham Heap

  • Ann Eldred

  • Philip Mease

Medical Centers

  • K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, Waterloo, ON, Canada

  • 2School of Medicine, Queen’s University, Kingston, ON and Skin Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada

  • Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  • Altoona Center for Clinical Research, Duncansville, PA

  • AbbVie, Inc., North Chicago, IL

  • Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

Locations

  • Canada

  • Japan

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Albumin/creatinine

Drug/Treatment

  • Risankizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT02986373

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved